Immunova Therapeutics LLC
- UEI
- J8RSMABQPN95
- CAGE
- 986W1
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- SAM.gov registration date
- Website
- immunovatherapeutics.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of CD4 TCR-engineered t cell immunotherapy in triple-negative breast cancer | National Cancer Institute (NIH) | $2,000,000 | |
| Development of a therapeutic sapnano-ESO vaccine for prostate cancer | National Cancer Institute (NIH) | $3,000,000 |
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of Southern California | R01CA302874 | $286,791 |
Similar vendors
About the company
Immunova Therapeutics LLC, a startup biopharmaceutical firm based in Monrovia, California, operates as a federal grant recipient developing T cell immunotherapy and therapeutic vaccine products for solid cancers under National Institutes of Health funding. The company holds two prime grants from the National Cancer Institute and sits as a sub-recipient on one additional NCI-funded award; across these three federal sources, Immunova has obligated $5.3 million and serves a single customer agency (the National Cancer Institute).
Immunova's federal footprint centers entirely on early-stage oncology immunotherapy development. The lead grant, awarded September 2024, funds development of CD4 TCR-engineered T cell immunotherapy (IMT-422 product) targeting triple-negative breast cancer, running through August 2027. The second prime grant, awarded August 2022 and completing July 2026, covers development of a self-assembled peptide nanoparticle (SAPNANO) vaccine (IMT-001 product) for NY-ESO-1-positive cancers including prostate cancer. The company also serves as a sub-recipient under a December 2025 University of Southern California grant for lung cancer immunotherapy using next-generation TCR-engineered CD4+ T cells. Two of the three awards (combined ultimate completion value spanning the next twenty-four months) face recompete or closeout within that window, creating near-term grant-continuation exposure for the company.
Immunova's federal grant work is exclusively research and development in cancer immunotherapy; the company does not hold federal contracts, IDVs, BPAs, or GWACs. Award activity is sparse and episodic — one award in 2022, one in 2024, one in 2025 — reflecting the startup stage and grant-driven funding model typical of early-stage biotech. The vendor does not compete under set-aside categories and does not appear as a subcontractor on federal contract work in the source data. Federal engagement is limited to National Cancer Institute project grants funding preclinical development and investigational new drug (IND)-enabling studies.
Quick answers
Is Immunova Therapeutics LLC registered in SAM.gov?
Immunova Therapeutics LLC's SAM.gov registration expired on October 22, 2026.
What is Immunova Therapeutics LLC's most recent federal award?
Immunova Therapeutics LLC's most recent federal grant award is Development of CD4 TCR-engineered t cell immunotherapy in triple-negative breast cancer (R44CA295183), from National Cancer Institute (NIH), on September 20, 2024.
On GovTribe
See Immunova Therapeutics LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors